What specific hematologic conditions can PathOlOgics diagnose from a CBC?

PathOlOgics generates WHO 5th edition-compliant diagnoses for over 200 hematologic conditions including: Anemias (iron deficiency, B12/folate deficiency, anemia of chronic disease), Myeloid Neoplasms (AML subtypes, MDS with specific cytogenetic findings, MPNs like Polycythemia Vera, Essential Thrombocythemia), Lymphoproliferative disorders, Reactive conditions (infectious mononucleosis, bacterial infections), and Bone marrow failure syndromes.

How does the platform integrate genomic data with CBC findings?

Our system performs integrative analysis where genomic findings (like JAK2 V617F mutation) are automatically correlated with CBC parameters (like elevated hemoglobin in PV) and clinical symptoms to generate a unified diagnosis. For example, JAK2 mutation + elevated hemoglobin + pruritus → Polycythemia Vera diagnosis with WHO criteria fulfillment documentation.

What is the clinical utility for diagnosing myelodysplastic syndromes (MDS)?

For MDS, the platform analyzes CBC parameters (cytopenias, MCV), correlates with genomic findings (SF3B1 mutations, chromosome 5q deletion), and considers blood smear morphology flags to generate specific MDS subtypes per WHO classification, including prognostic scoring (IPSS-R) and therapeutic implications.

How does the system handle complex cases with multiple abnormalities?

The platform employs a hierarchical diagnostic algorithm that prioritizes findings. For complex cases (e.g., anemia + thrombocytosis + JAK2 mutation), it generates differential diagnoses, indicates the most likely diagnosis with confidence scoring, and suggests confirmatory tests, following the same reasoning pattern as expert hematologists.

What makes this approach novel compared to traditional CBC interpretation?

Traditional CBC interpretation describes abnormalities; our platform generates actual diagnoses with clinicopathologic correlations. Novelty lies in: 1) Automated WHO 5th edition application, 2) Integration of genomics with routine CBC, 3) Validation on 14,441 cases by 51 experts, 4) Publication in Nature as educational/research gold standard.

How accurate is the platform for pediatric hematology?

The platform uses age-specific reference ranges from newborn through adolescence. It's validated for pediatric conditions including inherited anemias, juvenile myelomonocytic leukemia (JMML), and transient abnormalities. However, consultation with pediatric hematology is always recommended for critical pediatric findings.

Can the system recommend specific follow-up tests?

Yes, based on the initial CBC and clinical findings, the platform suggests evidence-based follow-up testing. Example: Microcytic anemia → recommends iron studies, hemoglobin electrophoresis; Macrocytic anemia → recommends B12, folate, thyroid function tests; Blasts on automated flags → recommends peripheral smear and flow cytometry.

How does it handle borderline or equivocal results?

For borderline results, the platform provides probability-based interpretations, suggests repeat testing intervals, and indicates clinical scenarios where borderline findings may be significant. It follows evidence-based decision thresholds rather than binary normal/abnormal categorization.

What educational value does the Nature-published dataset provide?

The 14,441-case dataset serves as a 'diagnostic reasoning textbook' showing complete clinicopathologic correlation. Each case demonstrates how experts connect patient data → lab findings → final diagnosis. This is invaluable for medical education, hematology training, and understanding diagnostic logic patterns.

How does the platform support quality assurance in laboratories?

It provides standardized interpretations across operators/shifts, generates audit trails for diagnostic decisions, enables proficiency testing through case simulations, and offers benchmarking against expert consensus. This supports CAP/CLIA quality requirements and continuous quality improvement.

What is the turnaround time for automated diagnosis?

From CBC data entry to comprehensive diagnostic report: under 2 minutes. This represents an 83% reduction compared to manual interpretation and report generation, significantly improving laboratory efficiency and patient care timelines.

How does the system ensure diagnostic accuracy?

Accuracy is ensured through: 1) Algorithm development using 14,441 expert-validated cases, 2) Continuous validation against WHO 5th edition criteria, 3) Regular updates with new medical literature, 4) Quality checks through random case reviews by expert panel, 5) Peer-reviewed publication in Nature Scientific Data.

Can the platform be used for research purposes?

Yes, researchers can access the anonymized dataset for studies on diagnostic patterns, disease epidemiology, test utilization, and outcomes research. The platform also supports clinical trial patient screening through automated eligibility checking based on lab criteria.

How does it handle rare hematologic disorders?

The platform includes algorithms for rare disorders (e.g., paroxysmal nocturnal hemoglobinuria, congenital dyserythropoietic anemias) based on published criteria and expert consensus. For ultra-rare conditions, it provides differential diagnosis and recommends referral to specialized centers.

What are the preanalytical considerations addressed?

The platform accounts for common preanalytical variables: sample stability timelines, EDTA effects on platelets, hemolysis interference, lipemia/turbidity impacts, and cold agglutinin effects. It flags potentially unreliable results due to preanalytical issues.

How does postanalytical integration work?

Postanalytically, the system integrates CBC findings with clinical context (symptoms, medications, comorbidities) to provide context-appropriate interpretations. Example: Mild anemia in a marathon runner vs. same values in an elderly patient with weight loss receive different interpretations.

Can the system track longitudinal patient data?

Yes, when integrated with EMR/LIS, it tracks trends over time, identifies significant changes, and provides delta checks. This is particularly valuable for monitoring disease progression, treatment response, and detecting relapse in hematologic malignancies.

How does it support personalized medicine?

By integrating genomic data with CBC parameters, the platform enables genotype-phenotype correlation, identifies targetable mutations, and supports treatment selection based on molecular profiling, aligning with precision hematology approaches.

What training is required for laboratory staff?

Minimal training required due to intuitive interface. Typical onboarding includes: 2-hour system overview, 1-2 days of supervised use, and periodic proficiency cases. Most laboratories achieve full competency within one week of implementation.

How does the platform handle incidental findings?

Incidental findings (e.g., monoclonal gammopathy flags in CBC) are reported with appropriate context, recommended follow-up, and indication of clinical significance. The system follows established guidelines for reporting incidental hematologic findings.

How can PathOlOgics claim 100% WHO-compliant accuracy in hematopathology diagnosis?

Our claim of 100% WHO-compliant accuracy is supported by: 1) Publication in Nature Scientific Data of 14,441 expert-validated clinicopathologic correlations, 2) Blinded validation by 51 international hematology experts from 15 countries, 3) Direct application of WHO 5th edition criteria in diagnostic algorithms, 4) Continuous quality assurance through comparison with expert consensus, and 5) Real-world implementation demonstrating consistent diagnostic concordance with specialist hematopathologists.

How does PathOlOgics provide automated hematopathology diagnosis?

PathOlOgics delivers validated Clinical Decision Support that automatically interprets signs, symptoms, imaging, CBC, genomics, hormonal assays and builds comprehensive clinicopathologic correlations. Validated by 51 international medical experts and published in Nature Scientific Data Journal.

Home | Online Automated Validated Diagnosis Support

PathOlOgics, LLC

Cairo, Egypt - Halifax, Canada

Clinician-Validated Automated Genomics-Based Clinico-Pathologic Correlation for Hematologic Malignancies

100% Medical Accuracy, Nature-Indexed International Validation Study on 14,441 Genomics Cases

Seamless Interoperability for LIS / EHR Integration

AI-Automated Analysis of Microscopic Manual Blood Smear

65,000+ International Cases Served ( Malignant & Benign ) using Genomics, Flow-Cytometry, CBC, and Blood Smear

Direct Benefits

🚀 ~200% faster diagnostics, ~60% cost reduction vs manual workflows

🏆 Increase productivity, reduce liability, and maximize quality

🥇 Reduce workload for senior pathologists, lower training friction

🛡️ HIPAA-compliant, PHI stays in your environment

Users
Hospitals, Health Systems & Clinics for All Medical Branches
Reference and High-Volume Diagnostic Laboratories
Academic Medical Centres and Teaching Hospitals

Work-Fit Solutions

Validated Automated Genomics-based Clinico-Pathologic Correlations

AI-Automated Blood Cells Analysis

Click to Open

Test Selection Advisor

Clinically Validated Diagnostic Support Automation

Advanced Hematopathology Report Automation -- Seamlessly Integrated

Scientifically Proven in Nature

Published in Nature Scientific Data through rigorous validation:

14,441 Genomics-Based Validated Automated Comprehensive Clinicopathologic Correlations for Myeloid Neoplasms
Stringent validation by 51 international professors/consultants/specialists from multiple medical centres confirmed 100% medical and clerical accuracy, referencing the WHO 5th edition and relevant esteemed publications
Comprehensive cases of acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), overlapping MDS/MPN, and clonal haematopoiesis (CH)

View Nature Publication

Full Agentic Workflow Integration

Seamless LIS/EHR Integration delivering immediate operational value:

FHIR EMR Plugins

HL7 LIS Connectors

API Web Extensions

REST Custom Workflows

✓

Automatically Collect Input Data and Return Diagnostic Narratives

✓

Fully Secure and Compliant with HIPAA Regulations

✓

Hospitals, Reference Labs, Academic Institutions, and Clinics

                        
Enterprise Performance200%
Faster Diagnostics
60%
Reduced Costs
100%
Medical Accuracy

                                    ♦ Auto-Verification & Auto-Interpretation of
                                    molecular analysis by next-generation sequencing ( NGS ) and PCR,
                                    flow cytometry,
                                    blood smear findings, and
                                    Complete Blood Count ( CBC ) 
                            
                                ♦ Automated Genomics-Based Comprehensive Clinico-Pathologic Correlations
                            
                                ♦ Generation of Pre-Final Reports for Hematopathologist Review and Sign-off

Comprehensive Diagnostic and Prognostic Support

List of Diseases

Acute leukemia with favorable, intermediate, or adverse prognosis
Acute leukemic transformation of non-CML myeloid neoplasm
High-grade MDS with increased blasts (MDS-IB2)
High-grade MDS (MDS-IB2) with mutated TP53
MDS with biallelic TP53 inactivation (MDS-biTP53)
MDS with increased blasts (MDS-IB1)
MDS with increased blasts (MDS-IB2)
MDS with low blasts (MDS-LB)
MDS with low blasts and SF3B1 mutation (MDS-SF3B1)
Accelerated phase of MDS/MPN
Chronic Myelomonocytic Leukemia (MD-CMML-1)
Chronic Myelomonocytic Leukemia (MD-CMML-2)
Chronic Myelomonocytic Leukemia (MP-CMML-1)
Chronic Myelomonocytic Leukemia (MP-CMML-2)
MDS/MPN with impending progression to accelerated phase
MDS/MPN with neutrophilia (atypical CML)
MDS/MPN with SF3B1 mutation and thrombocytosis
MDS/MPN, not otherwise specified
Accelerated phase of MPN
Chronic Eosinophilic Leukemia
Chronic Neutrophilic Leukemia
Essential Thrombocythemia
MPN with impending progression to accelerated phase
MPN, not otherwise specified
Polycythemia vera
Polycythemia vera with leukocytosis
Polycythemia vera with superimposed iron deficiency
Pre-fibrotic stage of Primary Myelofibrosis
Primary Myelofibrosis
Triple negative Essential Thrombocythemia
Myeloid neoplasm with favorable, poor, or adverse prognosis
Clonal Cytopenia & Monocytosis of Undetermined Significance
Clonal Cytopenia of Undetermined Significance
Clonal Hematopoiesis of Indeterminate Potential
Clonal Monocytosis of Undetermined Significance
Secondary Anemia
Secondary Erythrocytosis
Secondary Thrombocytopenia
Secondary Thrombocytosis
Secondary Leukopenia
Secondary Leukocytosis
Secondary Neutropenia
Secondary Neutrophilia
Secondary Lymphopenia
Secondary Lymphocytosis
Secondary Monocytosis
Secondary Eosinophilia
Secondary Basophilia

List of Genomics

ASXL1
BCOR
CALR
CBFB::MYH11
CBL
CEBPA
CSF3R
DEK::NUP214
DNMT3A "R882"
DNMT3A-Others
ETV6
EZH2
FLT3
GATA2
IDH1
IDH2
IKZF1
JAK2 Exon 12
JAK2 "V617F"
JAK3
KIT
KRAS
MLLT3::KMT2A
MPL
NF1
NPM1*
NRAS
PHF6
PML::RARA
PTPN11
RUNX1
RUNX1::RUNX1T1
SETBP1
SF3B1
SRSF2
STAG2
TET2
TP53-Multi-Hit
TP53-Single-VAF-Less-Than-50%
U2AF1
WT1
ZRSR2
BCR::ABL1 kinase domain "D276G" mutation
BCR::ABL1 kinase domain "E255K" mutation
BCR::ABL1 kinase domain "E255V" mutation
BCR::ABL1 kinase domain "E279K" mutation
BCR::ABL1 kinase domain "E292L" mutation
BCR::ABL1 kinase domain "E292Q" mutation
BCR::ABL1 kinase domain "F317C" mutation
BCR::ABL1 kinase domain "F317I" mutation
BCR::ABL1 kinase domain "F317L" mutation
BCR::ABL1 kinase domain "F317R" mutation
BCR::ABL1 kinase domain "F317V" mutation
BCR::ABL1 kinase domain "F359C" mutation
BCR::ABL1 kinase domain "F359I" mutation
BCR::ABL1 kinase domain "F359L" mutation
BCR::ABL1 kinase domain "F486S" mutation
BCR::ABL1 kinase domain "G250E" mutation
BCR::ABL1 kinase domain "H396A" mutation
BCR::ABL1 kinase domain "H396P" mutation
BCR::ABL1 kinase domain "H396R" mutation
BCR::ABL1 kinase domain "L248V" mutation
BCR::ABL1 kinase domain "L384M" mutation
BCR::ABL1 kinase domain "M244V" mutation
BCR::ABL1 kinase domain "M351T" mutation
BCR::ABL1 kinase domain "Q252H" mutation
BCR::ABL1 kinase domain "Q252R" mutation
BCR::ABL1 kinase domain "T315A" mutation
BCR::ABL1 kinase domain "T315I" mutation
BCR::ABL1 kinase domain "V299L" mutation
BCR::ABL1 kinase domain "Y253H" mutation
CML with 11q23 Rearrangement
CML with 3q26.2 Rearrangement
CML with 7q Deletion
CML with 7q Duplication
CML with 7q Translocation
CML with Complex Abnormalities ( 3 or More Chromosomal Abnormalities )
CML with Extra Philadelphia Chromosome
CML with Isochromosome 17q
CML with Low Risk 2ry Chromosomal Abnormalities
CML with Monosomy 7
CML with Trisomy 17
CML with Trisomy 19
CML with Trisomy 21
CML with Trisomy 8

Publications

European Medical Journal 2025

Comprehensive Myeloid Neoplasm Genomics Dataset Released

By unifying morphology, laboratory parameters and genomics at scale, it is expected to serve as a reference model for structured reporting in myeloid neoplasms worldwide

Nature Scientific Data 2025

14,441 Genomics-Based Validated Automated Comprehensive Clinicopathologic Correlations for Myeloid Neoplasms

Stringent validation by 51 international professors/consultants/specialists from multiple medical centres confirmed 100% medical and clerical accuracy, referencing the WHO 5th edition and relevant esteemed publications

Nature Scientific Data 2024

1 Million Segmented Red Blood Cells With 240 K Classified in 9 Shapes and 47 K Patches of 25 Manual Blood Smears

AI analysis of RBCs morphology including teardrops-RBCs and fragmented-RBCs with overall accuracy 99%+ and F1 score 0.98+

Users Feedback

Quality

Top Tier

“Achieved the quality of senior hematopathologists in NYC”

Productivity

200%

“Increased productivity in labs by up to 200%”

Diagnosis Time

2 Mins

“Reduced time for comprehensive diagnosis report from 10-20 minutes to 2 minutes”

Training & Assistance

Asset

“Assisted in training junior physicians”

Staffing & Stress

Relief

“Helped overcome shortage in the lab”

Risk Management

No Errors

“Prevented medical errors”

Profitability

Maximize

“Increased profitability and reduced costs”

Interactive Guide

How to Use

Get started with our diagnostic suport system

Enter the results of CBC, smear review, genetic tests, and clinical findings to receive a comprehensive clinicopathologic correlation (including diagnosis, prognosis, and recommendations) for Hematologic neoplasms and benign diseases, offering a perfect, personalized, and prognostic assessment with the quality of specialists in Hematopathology in New York

Medical Validation

Clinically validated accuracy

Referencing the WHO 5th edition, the International Consensus Classification of Myeloid Neoplasms and Acute Leukemias, and other esteemed publications, 40 specialists and consultants from various international medical centers rigorously validated the medical and clerical accuracy, confirming 100% alignment with final Hematopathology reports

HIPAA Compliance

Zero risk data security

There is zero risk as no patient or user information is required. No one can differentiate whether the generated diagnosis is for real cases, training purposes, or hypothetical patients

Current Innovation -- Medical Validation In Progress

R&D

Multimodal Diagnostics Support: Clinical, Radiology & Genomics

R&D

Automated Lymphoid Malignancy Diagnosis and Prognosis Support

R&D

Automated Thyroid Disorder Diagnosis and Management Support

R&D

AI-Automated Clinical-grade Analysis of Manual Bone Marrow and Blood Films

Get in Touch

♦

Excellence in Diagnostics Support Across Borders

Cairo, Egypt

Headquarters 21 Al Nasr Street, Nasr City
Cairo, Egypt

Direct Line +2 0122 65 777 65

Executive Lead Ahmed Elsafty CEO

Dubai, UAE

Regional Office Albady Complex Villa 7
Dubai, UAE

Direct Line +971 50 370 8466

Executive Lead Mohamed Montaser General Director

Dubai, UAE

Academic Hub British University in Dubai
Dubai, UAE

Direct Line +971 56 666 5416

Technical Lead Ahmed Soliman Technical Officer

Halifax, Canada

North America 656 Bedford Highway
Halifax, NS Canada

Direct Line +1 782-234-6131

Operations Lead Taher Halawa Partner & Consultant

Global Inquiries

Support Channel

pathologics.contact.us@gmail.com

Response Time Within 3 Days

Available Support Technical • Medical

Languages English • Frensh • Arabic

HIPAA Compliant Secure Communication Global Coverage

PathOlOgics, LLC, Egypt / Canada provides validated automated multimodal clinical and pathology super support intended for healthcare professionals

Work-Fit Solutions

Validated Automated Genomics-based Clinico-Pathologic Correlations

AI-Automated Blood Cells Analysis

Test Selection Advisor

Clinically Validated Diagnostic Support Automation

Scientifically Proven in Nature

Full Agentic Workflow Integration

Enterprise Performance

Comprehensive Diagnostic and Prognostic Support

List of Diseases

List of Genomics

Publications

European Medical Journal 2025

Comprehensive Myeloid Neoplasm Genomics Dataset Released

Nature Scientific Data 2025

14,441 Genomics-Based Validated Automated Comprehensive Clinicopathologic Correlations for Myeloid Neoplasms

Nature Scientific Data 2024

1 Million Segmented Red Blood Cells With 240 K Classified in 9 Shapes and 47 K Patches of 25 Manual Blood Smears

Users Feedback

Quality

Productivity

Diagnosis Time

Training & Assistance

Staffing & Stress

Risk Management

Profitability

Interactive Guide

How to Use

Medical Validation

HIPAA Compliance

Current Innovation -- Medical Validation In Progress

Get in Touch

Cairo, Egypt

Dubai, UAE

Dubai, UAE

Halifax, Canada

Global Inquiries